Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer: Current Use and Future Prospects

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Tyrosine kinase inhibitors (TKIs) are a cornerstone of targeted cancer therapy, offering improved outcomes and reduced side effects compared to traditional chemotherapy.
• Resistance to TKIs, often driven by epidermal growth factor receptor (EGFR) mutations, has led to the development of multiple TKI generations.

Purpose of the Study:

• To review the advancements in EGFR TKI therapy, detailing their mechanisms of action and the evolution of different TKI generations in overcoming resistance.
• To analyze the effectiveness of successive TKI generations against EGFR mutations, including T790M and emerging C797S mutations.

Main Methods:

• Literature review of clinical trials and research studies on EGFR TKIs.
• Analysis of progression-free survival (PFS) data across different TKI generations and treatment regimens.
• Evaluation of TKI efficacy against specific EGFR resistance mutations, such as T790M and C797S.

Main Results:

• First-generation TKIs (e.g., gefitinib) showed improved PFS over chemotherapy. Second-generation TKIs (e.g., afatinib) demonstrated superior efficacy compared to first-generation agents.
• Third-generation TKIs significantly increased survival rates and were effective against the T790M mutation.
• Emerging research indicates third-generation TKIs may be ineffective against non-small cell lung cancer (NSCLC) with the C797S mutation, necessitating further investigation.

Conclusions:

• EGFR TKIs have progressed significantly, with each generation offering enhanced efficacy and improved patient outcomes.
• Overcoming resistance, particularly to newer mutations like C797S, remains a critical area for ongoing research and development in TKI therapy.
• While promising in vitro and in vivo results exist for novel approaches against C797S, further clinical trials are required for regulatory approval.